{"organizations": [], "uuid": "87d5def4936c18947aa96655bdd491ec17094871", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-teva-reports-q1-non-gaap-earnings/brief-teva-reports-q1-non-gaap-earnings-per-share-0-94-idUSASC09ZGA", "country": "US", "domain_rank": 408, "title": "Teva Reports Q1 Non-GAAP Earnings Per Share $0.94", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-03T19:20:00.000+03:00", "replies_count": 0, "uuid": "87d5def4936c18947aa96655bdd491ec17094871"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-teva-reports-q1-non-gaap-earnings/brief-teva-reports-q1-non-gaap-earnings-per-share-0-94-idUSASC09ZGA", "ord_in_thread": 0, "title": "Teva Reports Q1 Non-GAAP Earnings Per Share $0.94", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "north america", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "teva", "sentiment": "negative"}, {"name": "teva pharmaceutical industries ltd", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "bla", "sentiment": "none"}, {"name": "teva pharmaceutical industries", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3 (Reuters) - Teva Pharmaceutical Industries Ltd :\n* TEVA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS * Q1 NON-GAAP EARNINGS PER SHARE $0.94\n* RAISING 2018 FULL YEAR GUIDANCE * RESTRUCTURING PLAN ON-TRACK TO ACHIEVE $1.5 BILLION OF SAVINGS IN 2018 AND $3.0 BILLION BY END OF 2019\n* 2018 FREE CASH FLOW GUIDANCE RAISED TO $3.0-3.2 BILLION FROM $2.6-2.8 BILLION\n* 2018 NON-GAAP EPS GUIDANCE RAISED TO $2.40-2.65 FROM $2.25-2.50\n* COPAXONE REVENUES IN OUR NORTH AMERICA SEGMENT IN Q1 OF 2018 DECREASED BY 40% TO $476 MILLION\n* COPAXONE REVENUES IN OUR EUROPE SEGMENT IN Q1 OF 2018 INCREASED BY 1% TO $153 MILLION\n* SEES 2018 REVENUES $18.5 BILLION TO $19.0 BILLION * TEVA PHARMACEUTICAL INDUSTRIES - GENERIC PRODUCTS REVENUE IN NORTH AMERICA SEGMENT IN Q1 2018 FELL BY 23% TO $1.1 BILLION, COMPARED TO Q1 OF 2017\n* TEVA PHARMACEUTICAL - DO NOT EXPECT TO RECEIVE FDA APPROVAL ON BIOLOGICS LICENSE APPLICATIONS (BLA) FOR FREMANEZUMAB ON MID-JUNE PDUFA DATE\n* TEVA PHARMACEUTICAL INDUSTRIES - GENERIC PRODUCTS REVENUE IN EUROPE SEGMENT IN Q1 2018, INCLUDING OTC PRODUCTS, ROSE 17% TO $997 MILLION, VERSUS Q1 2017\n* TEVA - REGARDING FREMANEZUMAB, CO SEES FDA PRE-APPROVAL INSPECTION TO TAKE PLACE IN COMING MONTHS & TO RECEIVE FDA APPROVAL & LAUNCH BEFORE 2018 END Source text for Eikon:\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-03T19:20:00.000+03:00", "crawled": "2018-05-04T16:32:32.042+03:00", "highlightTitle": ""}